Suchergebnisse
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Can-Fite BioPharma CANF shares soared 20.4% on Wednesday after the company reported positive top-line results from a mid-stage study of its investigational candidate, namodenoson, in patients with
